Clinical Trial

Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.

Study acronym: TMX
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety and tolerability of TMX in adults patients with cystic fibrosis who do not have mutations currently eligible for therapy with modulator drugs. The main questions it aims to answer is: . What medical problems do participants have when taking drug TMX? Participants will: * Take drug TMX every day for 6 months * Visit the clinic once every 28 days for checkups and tests
Trial Details
NCT Number NCT07289035
Lead Sponsor Azienda Ospedaliera Universitaria Integrata Verona
Conditions Cystic Fibrosis - Complete
Enrollment 35 participants
Start Date 2026-01-15
Primary Completion 2026-04-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-17